Clinical Trials Browser

Phase 2 × Paraganglioma × olaparib × Clear all

NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma